Digest Network Come funziona
Network
/
Società
Ge
Non verificato

GenSight Biologics

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOtticaSalute

17 comunicati stampa

Guarda tutti i comunicati
02/12/2025
Salute
Biotecnologia
Medicina - Varie
Farmaceutica
Ottica
Industria
GenSight Biologics Announces Regulatory Approval for GS010/LUMEVOQ® REVISE Dose-Ranging Study in France
Fonte
GenSight Biologics
Emittente
Business Wire
1.00
0
30/10/2025
Industria
Attrezzature medico-sanitarie
Igiene alimentare
Biotecnologia
Farmaceutica
Salute
Ottica
GenSight Biologics Announces Regulatory Authorizations for Individual Patient Expanded Access Treatment with GS010/LUMEVOQ® in the US
Fonte
GenSight Biologics
Emittente
Business Wire
1.00
0
07/10/2025
Salute
Biotecnologia
Scienza
Farmaceutica
Ottica
Mercato azionario
Pubblico Esercizio/Vendita al dettaglio
GenSight Biologics Reports Cash Position as of September 30, 2025
Fonte
GenSight Biologics
Emittente
Business Wire
1.00
0
29/09/2025
Attrezzature medico-sanitarie
Salute
Medicina - Varie
Farmaceutica
Ottica
Biotecnologia
Mercato azionario
GenSight Biologics Reports Interim Financial Results for the First Half of 2025
Fonte
GenSight Biologics
Emittente
Business Wire
1.00
0
17/07/2025
Salute
Biotecnologia
Sanità
Medicina - Varie
Farmaceutica
Industria
GenSight Biologics Announces Publication on Predictors of Final Visual Outcome in Patients Treated with LUMEVOQ® Gene Therapy
Fonte
GenSight Biologics
Emittente
Business Wire
1.00
0
08/07/2025
Salute
Biotecnologia
Medicina - Varie
Farmaceutica
GenSight Biologics Reports Cash Position as of June 30, 2025
Fonte
GenSight Biologics
Emittente
Business Wire
1.00
0
26/06/2025
Salute
Biotecnologia
Medicina - Varie
Farmaceutica
Ottica
Mercato del lavoro
GenSight Biologics Announces Significant Milestone in New Manufacturing Partnership with Catalent
Fonte
GenSight Biologics
Emittente
Business Wire
1.00
0
12/06/2025
Biotecnologia
Salute
Farmaceutica
Industria
GenSight Biologics Reaches Agreement with ANSM for Opening of LUMEVOQ® Named Early Access Program (AAC) in France
Fonte
GenSight Biologics
Emittente
Business Wire
1.00
0
13/05/2025
Web e Social Network
Salute
Biotecnologia
Medicina - Varie
Farmaceutica
Ottica
GenSight Biologics Announces Approval of All Resolutions Supported by the Board of Directors at the Combined General Meeting of May 13, 2025
Fonte
GenSight Biologics
Emittente
Business Wire
1.00
0
23/04/2025
Web e Social Network
Scienza
Biotecnologia
Farmaceutica
Ottica
Salute
GenSight Biologics Annual General Meeting on May 13, 2025
Fonte
GenSight Biologics
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0